Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications.

ABSTRACT: Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood-brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity's olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal ad

SUBMITTER: Talens-Visconti R 

PROVIDER: S-EPMC10223127 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature